Renata Medical’s Minima Growth Stent has found its way into its first patient. 
 
“This is the beginning of something special,” said Dr. Darren Berman, director of Congenital Interventional Catheterization at Children’s Hospital Los Angeles. “With the very recent FDA approval of Renata Medical’s Minima Stent, we now have a stent specifically designed to treat some of the most common congenital heart defects in our youngest patients. We implanted the first commercially available Minima Stent in a 2-year-old child with severe branch pulmonary artery stenosis. The procedure went smoothly, and she went home the next day.”
 
Approved by the U.S. Food and Drug Administration in August, the Minima Growth Stent is a device designed to support somatic growth and was developed to address the limitations of traditional stenting methods in young children. Its Growth Technology is designed to support aortic coarctation and pulmonary artery stenosis relief and re-expand as the patient grows. 
 
“Successfully implanting the first commercial Minima Growth Stent is a monumental achievement for our company,” Renata Medical CEO Dustin Armer stated. “This milestone reflects our commitment to advancing medical technology and improving patient lives. We are excited to see the positive outcomes this stent will bring to the medical community and the patients we serve.”
 
Renata Medical, a Delaware corporation, was founded in 2019 with the focus on creating cardiovascular devices for unmet pediatric needs. Renata develops, manufactures, and sells technology for pediatric patients.